Apigenin derivative or solvate or pharmaceutically acceptable salt thereof and application of apigenin derivative or solvate or pharmaceutically acceptable salt thereof in preparation of uric acid reducing medicine
By grafting and derivatizing apigenin, apigenin derivative with stronger uric acid reduction effect was prepared, which solved the problems of limited effects of existing apigenin and side effects of traditional drugs, and achieved safer and more efficient blood Uric acid reduction effect.
Patent Information
- Application Number
- CN202410934404.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-07-12
AI Technical Summary
The existing apigenin or celery seeds have limited effects in reducing uric acid, and traditional chemical synthetic drugs have toxic side effects, so it is necessary to develop a natural drug with better uric acid reduction effect.
By derivatizing apigenin, apigenin derivatives were prepared by carnosine grafting method, combining dimethyl sulfoxide and carnosine reactions, and triethylamine was added to the product to form a compound with stronger uric acid-lowering effect.
This apigenin derivative significantly reduced the blood uric acid level in the experiment, and has a better uric acid reduction effect than benzylbromalone, and has reduced side effects on the human body due to its origin from food nutrients.
Smart Images

Figure BDA0004940852040000021 
Figure BDA0004940852040000101 
Figure BDA0004940852040000111
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and more specifically, relates to an apigenin derivative or a solvate or a pharmaceutically acceptable salt thereof and an application thereof in the preparation of a uric acid-lowering drug. Background Art
[0002] Hyperuricemia is a metabolic disease characterized by elevated uric acid levels in the blood. Uric acid is the final product of purine metabolism in the human body, and the normal standard for blood uric acid levels is less than 360mmol / L (6mg / dL) for women and less than 400μmol / L (6.8mg / dL) for men. The occurrence of hyperuricemia is related to multiple factors, such as lifestyle, nutritional balance, medication, gender, age, and genetics. In particular, unbalanced nutrition and increased alcohol consumption in young people have led to an increased prevalence of the disease in these populations. Long-term onset of hyperuricemia can lead to hypertension, hyperlipidemia, hyperglycemia, gouty arthritis, kidney stones, renal failure, and cardiovascular diseases. According to a 2004 national survey conducted by the National Center for Disease and Health Research in China, more than 120 million cases of hyperuricemia were reported in China. Therefore, there is an urgent need to develop strategies for the treatment and prevention of hyperuricemia. There are already drugs for treating hyperuricemia, such as allopurinol and benzbromarone, which are obtained through chemical synthesis methods. These synthetic drugs usually have some toxic side effects, while drugs synthesized from natural drugs have fewer toxic side effects.
[0003] Apigenin, also known as apigenin, is a naturally occurring flavonoid compound that is widely found in a variety of fruits, vegetables and beans, with the highest content in celery. Existing studies have found that apigenin can significantly inhibit the activity of xanthine oxidase, and its uric acid-lowering effect is similar to allopurinol. At present, foreign countries have developed health products specifically for gout patients with celery seeds as the main ingredient.
[0004] However, the uric acid-lowering effect of apigenin or celery seeds is limited and still needs to be further improved. Summary of the invention
[0005] 1. Problem to be solved
[0006] In order to further solve the technical problem of lowering blood uric acid, the purpose of the present invention is to provide an apigenin derivative and its application in lowering uric acid, the compound has a better uric acid lowering effect than benzbromarone; further, the compound is prepared by the method of apigenin grafted carnosine, both of which are food nutrients and can minimize the side effects of blood uric acid lowering drugs on the human body.
[0007] 2. Technical solution
[0008] In order to solve the above problems, the present invention attempts to derivatize apigenin in order to improve its uric acid-lowering effect.
[0009] Carnosine belongs to the histidine dipeptide family, is composed of β-alanine and L-histidine, and is naturally present in vertebrate skeletal muscle and brain tissue. As a food nutrient, carnosine has many biologically active functions, including anti-oxidation, anti-fatigue, anti-aging and anti-inflammatory effects. Based on its antioxidant and anti-inflammatory properties, carnosine helps to repair liver and kidney dysfunction in various diseases. For example, carnosine was found to have a protective effect on hydrogen peroxide-induced human kidney oxidative stress and effectively reduce renal damage in diabetic rats. The effect of carnosine on reducing blood uric acid in hyperuricemic rats is achieved by inhibiting inflammation to enhance uric acid excretion and restore liver and kidney dysfunction. Based on this, the present invention adopts carnosine grafted with apigenin to achieve the purpose of enhancing the uric acid-lowering effect of apigenin.
[0010] The technical solution adopted by the present invention is as follows:
[0011] The technical solution of the present invention is as follows:
[0012] The first aspect of the present invention provides an apigenin derivative or a solvate or a pharmaceutically acceptable salt thereof, wherein the apigenin derivative has a structure shown in the following formula (I):
[0013]
[0014] The molecular formula of the apigenin derivative is C 26 H 22 N4O7.
[0015] The second aspect of the present invention provides a method for preparing the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect, comprising the step of reacting apigenin with carnosine.
[0016] As a preferred method for preparing the apigenin derivative or its solvate or pharmaceutically acceptable salt according to the second aspect of the present invention, the preparation method comprises:
[0017] i. a step of reacting apigenin with dimethyl sulfoxide;
[0018] ii. a step of reacting the product of step i with carnosine.
[0019] As a preferred method for preparing the apigenin derivative or its solvate or pharmaceutically acceptable salt according to the second aspect of the present invention, the preparation method further comprises:
[0020] iii. A step of adding triethylamine to the product of step ii.
[0021] The third aspect of the present invention provides use of the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect in the preparation of a drug for lowering blood uric acid.
[0022] According to the application of any embodiment of the third aspect of the present invention, the blood uric acid lowering drug comprises:
[0023] Drugs that lower blood uric acid by promoting uric acid excretion; or
[0024] Drugs that lower blood uric acid by inhibiting uric acid production; or
[0025] Medications that lower serum uric acid by inhibiting uric acid reabsorption; or
[0026] A drug that lowers blood uric acid and is characterized by catalyzing the conversion of uric acid.
[0027] According to the application of any embodiment of the third aspect of the present invention, the drug for lowering blood uric acid is used to treat hyperuricemia.
[0028] The fourth aspect of the present invention provides a pharmaceutical composition, which contains the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect as the only active ingredient or as one of the active ingredients.
[0029] The fourth aspect of the present invention provides a pharmaceutical composition, which further comprises a pharmaceutically acceptable excipient or carrier.
[0030] According to the pharmaceutical composition of any embodiment of the fourth aspect of the present invention, the amount of the apigenin derivative or its solvate or pharmaceutically acceptable salt contained in the pharmaceutical composition or the dose to be administered is 10 to 2000 mg.
[0031] Preferably, it is 50 to 1000 mg.
[0032] More preferably, it is 100 to 800 mg.
[0033] The most preferred range is 200 to 500 mg.
[0034] On this basis, the amount of the apigenin derivative or its solvate or pharmaceutically acceptable salt contained in the pharmaceutical composition or the size of the dose to be administered can be any value within any of the following numerical ranges:
[0035] 10~2000mg, 10~1500mg, 10~1200mg, 10~1000mg, 10~900mg, 10~800mg, 10~700mg, 10~600mg, 10~500mg, 10~400mg, 10~300mg, 10~200mg, 10~100mg;
[0036] 50~2000mg, 50~1500mg, 50~1200mg, 50~1000mg, 50~900mg, 50~800mg, 50~700mg, 50~600mg, 50~500mg, 50~400mg, 50~300mg, 50~200mg, 50~100mg;
[0037] 100~1000mg, 100~900mg, 100~800mg, 100~700mg, 100~600mg, 100~500mg, 100~400mg, 100~300mg, 100~200mg;
[0038] 200~1000mg, 200~900mg, 200~800mg, 200~700mg, 200~600mg, 200~500mg, 200~400mg, 200~300mg;
[0039] 300~1000mg, 300~900mg, 300~800mg, 300~700mg, 300~600mg, 300~500mg, 300~400mg;
[0040] 400~1000mg, 400~900mg, 400~800mg, 400~700mg, 400~600mg, 400~500mg;
[0041] 500~1000mg, 500~900mg, 500~800mg, 500~700mg, 500~600mg;
[0042] 600~1000mg, 600~900mg, 600~800mg, 600~700mg;
[0043] 700~1000mg, 700~900mg, 700~800mg;
[0044] 800-1000mg, 800-900mg;
[0045] 900~1000mg.
[0046] When administered at the above dosage, satisfactory effects can be obtained, preferably 1, 2, 3 times a day as a whole or in multiple divided doses, or in a sustained release form. This dosage regimen can be adjusted to provide the best therapeutic response. For example, several divided doses can be administered daily, or the dosage can be reduced proportionally, depending on the urgency of the treatment situation.
[0047] According to the pharmaceutical composition of any embodiment of the fourth aspect of the present invention, the dose to be administered is a single dose.
[0048] According to the pharmaceutical composition of any embodiment of the fourth aspect of the present invention, the dose to be administered is a daily dose.
[0049] According to any embodiment of the fourth aspect of the present invention, the pharmaceutical composition is administered once, twice or three times a day.
[0050] According to any embodiment of the fourth aspect of the present invention, the pharmaceutical composition is a pharmaceutical composition for administration via the gastrointestinal tract.
[0051] According to any embodiment of the fourth aspect of the present invention, the pharmaceutical composition is a pharmaceutical composition for administration by injection.
[0052] According to any embodiment of the fourth aspect of the present invention, the pharmaceutical composition is a pharmaceutical composition for administration via subcutaneous implantation.
[0053] The dosage form of the pharmaceutical composition of the present invention can be varied, as long as it is a dosage form that can effectively allow the active ingredient to reach the mammalian body. For example, it can be selected from: powders, powders, tablets, pills, capsules, sustained-release agents, controlled-release agents, injections, infusions, and suspensions. According to the type of disease treated by the composition of the present invention, those skilled in the art can choose a dosage form that is convenient for use. From the perspective of ease of preparation and storage, the preferred pharmaceutical composition is a solid composition, especially a tablet and a solid-filled or liquid-filled capsule. From the perspective of ease of administration, the preferred pharmaceutical composition is an oral preparation. The pharmaceutical composition of the present invention can also be stored in a sterilizing apparatus suitable for injection or instillation.
[0054] Pharmaceutical compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules, which may be prepared with coatings as appropriate.
[0055] Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
[0056] The formulation and preparation of the pharmaceutical compositions of the present invention in the form of these pharmaceutical preparations can be achieved by methods and experience known to those skilled in the art.
[0057] According to any embodiment of the fourth aspect of the present invention, the pharmaceutical composition has the following dosage forms: powder, granules, tablets, pills, capsules, sustained-release agents, controlled-release agents, injections, infusions, and suspensions.
[0058] As a pharmaceutical composition, it can be widely used as medicine, functional health products, etc. Specifically, for example, tablets (including plain tablets, sugar-coated tablets, film-coated tablets, sublingual tablets, oral disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules, microcapsules), tablets, syrups, liquids, emulsions, suspensions, controlled release preparations (such as quick-release preparations, sustained-release preparations, sustained-release microcapsules), aerosols, films (such as oral disintegrating films, oral mucosal films), percutaneous absorption preparations, ointments, lotions, patches, pellets, nasal preparations, oral preparations or parenteral preparations such as pulmonary preparations (inhalants) can be listed. As long as the pharmaceutical composition of the present invention contains the active ingredient of formula (I) of the present invention, it can be prepared by appropriately coordinating the carriers, bases and / or additives commonly used in the preparation field within the scope of achieving the purpose of the present invention according to a conventional method.
[0059] The fifth aspect of the present invention provides a medicine kit, which includes the apigenin derivative or its solvate or pharmaceutically acceptable salt provided by any embodiment of the first aspect of the present invention, and a pharmaceutically acceptable carrier, or includes the pharmaceutical composition of any embodiment of the fourth aspect of the present invention.
[0060] The sixth aspect of the present invention provides use of the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect in preventing, treating or alleviating hyperuricemia.
[0061] According to the application of any embodiment of the sixth aspect of the present invention, the treatment of hyperuricemia comprises:
[0062] Promote uric acid excretion; or
[0063] Inhibit uric acid production; or
[0064] Inhibit uric acid reabsorption; or
[0065] Catalyzes the conversion of uric acid.
[0066] According to the application of the sixth aspect of the present invention, the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect is administered as the sole active ingredient of the drug, or the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect is administered as one of the active ingredients to achieve the therapeutic purpose.
[0067] According to the use of any embodiment of the sixth aspect of the present invention, the amount of the apigenin derivative or its solvate or pharmaceutically acceptable salt or the dosage to be administered is 10 to 2000 mg.
[0068] Preferably, it is 50 to 1000 mg.
[0069] More preferably, it is 100 to 800 mg.
[0070] The most preferred range is 200 to 500 mg.
[0071] On this basis, the amount of the apigenin derivative or its solvate or pharmaceutically acceptable salt or the size of the dose to be administered can be any value within any of the following numerical ranges:
[0072] 10~2000mg, 10~1500mg, 10~1200mg, 10~1000mg, 10~900mg, 10~800mg, 10~700mg, 10~600mg, 10~500mg, 10~400mg, 10~300mg, 10~200mg, 10~100mg;
[0073] 50~2000mg, 50~1500mg, 50~1200mg, 50~1000mg, 50~900mg, 50~800mg, 50~700mg, 50~600mg, 50~500mg, 50~400mg, 50~300mg, 50~200mg, 50~100mg;
[0074] 100~1000mg, 100~900mg, 100~800mg, 100~700mg, 100~600mg, 100~500mg, 100~400mg, 100~300mg, 100~200mg;
[0075] 200~1000mg, 200~900mg, 200~800mg, 200~700mg, 200~600mg, 200~500mg, 200~400mg, 200~300mg;
[0076] 300~1000mg, 300~900mg, 300~800mg, 300~700mg, 300~600mg, 300~500mg, 300~400mg;
[0077] 400~1000mg, 400~900mg, 400~800mg, 400~700mg, 400~600mg, 400~500mg;
[0078] 500~1000mg, 500~900mg, 500~800mg, 500~700mg, 500~600mg;
[0079] 600~1000mg, 600~900mg, 600~800mg, 600~700mg;
[0080] 700~1000mg, 700~900mg, 700~800mg;
[0081] 800-1000mg, 800-900mg;
[0082] 900~1000mg.
[0083] When administered at the above dosage, satisfactory effects can be obtained, preferably 1, 2, 3 times a day as a whole or in multiple divided doses, or in a sustained release form. This dosage regimen can be adjusted to provide the best therapeutic response. For example, several divided doses can be administered daily, or the dosage can be reduced proportionally, depending on the urgency of the treatment situation.
[0084] According to any embodiment of the sixth aspect of the present invention, the dose to be administered is a single dose.
[0085] According to any embodiment of the sixth aspect of the present invention, the dose to be administered is a daily dose.
[0086] According to any embodiment of the sixth aspect of the present invention, the apigenin derivative or its solvate or pharmaceutically acceptable salt is administered once, twice or three times a day.
[0087] According to the application of any embodiment of the sixth aspect of the present invention, the apigenin derivative or its solvate or pharmaceutically acceptable salt is administered via the gastrointestinal tract.
[0088] According to the application of any embodiment of the sixth aspect of the present invention, the apigenin derivative or its solvate or pharmaceutically acceptable salt is a pharmaceutical composition for administration by injection.
[0089] According to the application of any embodiment of the sixth aspect of the present invention, the apigenin derivative or its solvate or pharmaceutically acceptable salt is a pharmaceutical composition administered by subcutaneous implantation.
[0090] The seventh aspect of the present invention provides the use of the apigenin derivative or its solvate or pharmaceutically acceptable salt described in the first aspect in the preparation of functional food.
[0091] According to any embodiment of the sixth aspect of the present invention, the amount of the compound or its solvate or pharmaceutically acceptable salt contained in the functional food or the dosage to be taken is 10 to 2000 mg.
[0092] Preferably, it is 50 to 1000 mg.
[0093] More preferably, it is 100 to 800 mg.
[0094] The most preferred range is 200 to 500 mg.
[0095] On this basis, the amount of the compound of formula (I) or its solvate or pharmaceutically acceptable salt contained in the functional food or the size of the dose to be administered can be any value within any of the following numerical ranges:
[0096] 10~2000mg, 10~1500mg, 10~1200mg, 10~1000mg, 10~900mg, 10~800mg, 10~700mg, 10~600mg, 10~500mg, 10~400mg, 10~300mg, 10~200mg, 10~100mg;
[0097] 50~2000mg, 50~1500mg, 50~1200mg, 50~1000mg, 50~900mg, 50~800mg, 50~700mg, 50~600mg, 50~500mg, 50~400mg, 50~300mg, 50~200mg, 50~100mg;
[0098] 100~1000mg, 100~900mg, 100~800mg, 100~700mg, 100~600mg, 100~500mg, 100~400mg, 100~300mg, 100~200mg;
[0099] 200~1000mg, 200~900mg, 200~800mg, 200~700mg, 200~600mg, 200~500mg, 200~400mg, 200~300mg;
[0100] 300~1000mg, 300~900mg, 300~800mg, 300~700mg, 300~600mg, 300~500mg, 300~400mg;
[0101] 400~1000mg, 400~900mg, 400~800mg, 400~700mg, 400~600mg, 400~500mg;
[0102] 500~1000mg, 500~900mg, 500~800mg, 500~700mg, 500~600mg;
[0103] 600~1000mg, 600~900mg, 600~800mg, 600~700mg;
[0104] 700~1000mg, 700~900mg, 700~800mg;
[0105] 800-1000mg, 800-900mg;
[0106] 900~1000mg.
[0107] According to the use of any embodiment of the seventh aspect of the present invention, the functional food is a functional beverage.
[0108] According to the application of any embodiment of the seventh aspect of the present invention, the functional beverage is an alcoholic beverage, including beer, liquor or medicinal wine.
[0109] The eighth aspect of the present invention provides a functional food comprising the apigenin derivative or a solvate or a pharmaceutically acceptable salt thereof according to the first aspect.
[0110] As functional food, for example, diet composition, can be used as diet, diet additive and be widely utilized.Specifically, except for various foods such as bread, cake, noodles, dessert, jelly, frozen food, ice cream, dairy products, beverage, soup, edible oil, juice beverage, carbonated beverage, tea beverage, sports drink, milk beverage, alcoholic beverage, refreshing drink etc. can also be listed.In addition, diet also comprises functional label food, nutritional function food, specific health food, special purpose food, food for the elderly, food for patients, health supplement food (supplement).These forms are not particularly limited, can be the form of the oral administration type of above-mentioned medicine, quasi-medical product.It should be noted that these can be the compositions formed by adding preventive agent and / or therapeutic agent of the present invention when preparing or after preparing existing diet, and adding period, adding method are not particularly limited.
[0111] According to any embodiment of the eighth aspect of the present invention, the functional food is a functional beverage.
[0112] According to the functional food of any embodiment of the eighth aspect of the present invention, the functional beverage is an alcoholic beverage, including beer, liquor or medicinal wine.
[0113] Any embodiment of any aspect of the present invention can be combined with other embodiments without contradiction. In addition, in any embodiment of any aspect of the present invention, any technical feature can be applied to the technical feature in other embodiments without contradiction.
[0114] Under the premise that there is no contradiction, any technical feature possessed by any aspect of the present invention or any implementation scheme of any aspect is also applicable to any other implementation scheme or any implementation scheme of any other aspect. Of course, when applicable to each other, the corresponding features may be appropriately modified if necessary.
[0115] The term "solvate" used herein refers to a compound that carries solvent molecules, for example, the solvate may be a hydrate.
[0116] In the present invention, the term "comprising" or "containing" means that the active ingredient can be applied together with other components in the pharmaceutical composition or functional food of the present invention.
[0117] The composition of the present invention also includes isomers, solvates, precursors, or pharmaceutically acceptable salts thereof of the specific compound in the pharmaceutical composition, as long as they have the same or substantially the same function as the specific compound in the composition.
[0118] In the present invention, "pharmaceutically acceptable" ingredients are substances that are suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), that is, substances with a reasonable benefit / risk ratio.
[0119] In the present invention, "pharmaceutically acceptable salts" refer to acid addition salts of compounds with non-toxic acids, including salts formed by reactions of inorganic acids, organic acids, alkali metals or alkaline earth metals. These salts include but are not limited to:
[0120] (1) Salts formed with the following inorganic acids: such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid;
[0121] (2) Salts formed with organic acids such as acetic acid, oxalic acid, succinic acid, tartaric acid, methanesulfonic acid, maleic acid, or arginine. Other salts include salts formed with alkali metals or alkaline earth metals (such as sodium, potassium, calcium or magnesium) in the form of esters, carbamates, or other conventional "prodrugs".
[0122] The compounds in the compositions of the present invention have one or more asymmetric centers and may therefore exist as racemic mixtures, individual enantiomers, individual diastereomers, diastereomeric mixtures, cis- or trans-isomers.
[0123] In the present invention, "pharmaceutically acceptable carrier" is a pharmaceutically or food acceptable solvent, suspending agent or excipient used to deliver the composition, isomer, solvate, or pharmaceutically acceptable salt thereof of the present invention to animals or humans. The carrier may be liquid or solid.
[0124] The "pharmaceutically acceptable carriers or excipients" in the present invention include but are not limited to preservatives, wetting agents, emulsifiers and dispersants.
[0125] The pharmaceutical composition of the present invention can be used as the sole drug, or can be used in combination with one or more other drugs that have synergistic and / or synergistic effects with the substance of the present invention on physiological activity. Combination therapy can be achieved by administering the individual therapeutic components simultaneously, sequentially or separately.
[0126] The actual dosage level and mode of administration of the active ingredients in the pharmaceutical compositions of the present invention may be varied so that the amount of active substance obtained is effective to obtain the desired therapeutic response for a particular patient. The dosage level must be selected based on the activity of the specific active substance, the route of administration, the severity of the condition being treated, and the condition and medical history of the patient being treated. However, it is common practice in the art to start the dosage of the active substance at a level below that required to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained.
[0127] When used for the above-mentioned treatment and / or prevention of the present invention or other treatment and / or prevention, a pharmaceutical composition of the present invention in a therapeutic and / or preventive effective amount can be used in a separate form. Alternatively, the pharmaceutical composition of the present invention can be administered in combination with one or more pharmaceutically acceptable carriers or excipients.
[0128] The term "treatment" in the present invention means managing and caring for a patient for the purpose of combating a condition (e.g., a disease or disorder). The term is intended to include the full range of treatments for a given condition suffered by a patient, such as administering a composition to relieve symptoms or complications, to delay the progression of the condition, and / or to cure or eliminate the condition. The patient to be treated is preferably a mammal, particularly a human being.
[0129] The term "therapeutically and / or prophylactically effective amount" of the pharmaceutical composition of the present invention in the present invention refers to an amount sufficient to cure, alleviate or partially prevent the clinical manifestations of a given disease and its complications in a therapeutic intervention including the administration of the pharmaceutical composition. The amount sufficient to achieve the above is defined as a "therapeutically and / or prophylactically effective amount". The effective amount for each purpose will depend on the severity of the disease or injury and the weight and general condition of the subject. However, it should be recognized that the total daily dose of the pharmaceutical composition of the present invention must be determined by the attending physician within the scope of sound medical judgment. For any specific patient, the specific therapeutically effective dosage level must be determined based on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific pharmaceutical composition used; the specific pharmaceutical composition used; the patient's age, weight, general health, sex and diet; the administration time, route of administration and excretion rate of the specific pharmaceutical composition used; the duration of treatment; other drugs used in combination or simultaneously with the pharmaceutical composition used; and similar factors known in the medical field. For example, the practice in the art is to start the dosage of the pharmaceutical composition from a level lower than that required to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained.
[0130] The compound (active ingredient) in the pharmaceutical composition used in the present invention can be administered alone as a pure compound in a single dose or multiple doses, or in combination with a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition according to the present invention can be formulated with a pharmaceutically acceptable carrier or excipient and any other known adjuvant and vehicle according to conventional techniques.
[0131] 3. Beneficial effects
[0132] Compared with the prior art, the present invention has the beneficial effects of providing a new compound with better blood uric acid lowering effect. Compared with the raw materials apigenin, carnosine and the traditional positive drug benzbromarone which also have the effect of lowering blood uric acid, the compound has a better effect of lowering blood uric acid. At the same time, apigenin and carnosine both have excellent biocompatibility, which greatly increases the market prospects of the apigenin derivatives of the present invention and is expected to contribute to the preparation of uric acid lowering drugs. DETAILED DESCRIPTION
[0133] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0134] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.
[0135] Concentration, amount and other numerical data can be presented in range format herein.It should be understood that such range format is only used for convenience and simplicity, and should be flexibly interpreted as not only including the numerical value clearly described as range limit, but also including all single numerical values or sub-ranges contained in the range, just as each numerical value and sub-range are clearly described.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly described, but also including single numerals (such as 2,3,4) and sub-ranges (such as 1 to 3,2 to 4, etc.).The same principle is applicable to the scope of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all the above-mentioned values and ranges.In addition, no matter how the breadth of the described range or feature is, this explanation should be applicable.
[0136] The present invention is further described below in conjunction with specific embodiments.
[0137] Example 1
[0138] Preparation of the compound of formula (I) (Compound 3) (Quercetin-3-O-glucuronide coupled with (1-benzyl-4-piperidinyl)methylamine compound)
[0139]
[0140] Apigenin (270 mg, 1 mmol) was dissolved in 1,4-dioxane (25 mL), and thionyl chloride (9.4 mL, 0.13 mol) was added dropwise, and the resulting mixed solution was stirred at 70°C for 4 hours, and the stirred mixed solution was concentrated in vacuo. The concentrated solid was added to 1,4-dioxane (25 mL) and a certain amount of carnosine (272 mg, 1.2 mmol) was added, and the mixed solution was stirred at 70°C for 2 hours. Triethylamine (8.3 mL), ethanol (4.1 mL) and water (8.3 mL) were added to the stirred mixed solution, and then the mixed solution was concentrated again. The concentrated solid was extracted two to three times with diethyl ether (50 mL) and water (15 mL), the diethyl ether was separated and the excess water was removed with anhydrous sodium sulfate, and the mixture was concentrated in vacuo and purified by silica gel column chromatography, dichloromethane: methanol = 100: 1, to obtain the compound of formula (I) (434 mg, 0.91 mmol, 91%).
[0141] H NMR spectrum of compound 3: 1H NMR (500MHz, Chloroform-d) δ8.50 (s, 1H), δ8.90 (s, 1H), δ7.97 (d, J = 9.5Hz, 1H), 7.91-7.85 (m, 2H), 7.53 (d d,J=5.9,1.6Hz,1H),7.25-7.19(m,2H),6.82(dd,J=4.8,1.6Hz,1H),6.75(s,1H),6.52(d,J=1.8Hz,1H),6.2 5(d,J=1.8Hz,1H),4.68(dt,J=9.7,6.7Hz,1H),4.23(dd,J=5.9,4.9Hz,1H),3.35(t,J=6.6Hz,2H),3.09(dd ,J=14.6,6.8Hz,1H),3.03(dd,J=14.7,6.8Hz,1H),2.87(ttd,J=6.4,4.9,1.6Hz,2H),2.35(d,J=9.7Hz,2H).
[0142] Example 2
[0143] Effect of compound 3 on blood uric acid in experimental mice
[0144] Sixty male mice were randomly selected, with 10 mice in each group, and randomly divided into 6 groups: positive group (benzbromarone), normal saline group, CMC model group, high, medium and low dose groups of compound 3, and raw material (apigenin and carnosine) control group.
[0145] Reagent preparation:
[0146] (1) Preparation of CMC-Na solution (0.8%): Weigh 2.4 g of CMC-Na, first mix it into a lake state with a small amount of purified water, then make up to 300 ml with purified water, pour it into a beaker and boil it to completely dissolve it, then pour it into a volumetric flask and make up to 300 ml with purified water.
[0147] (2) Preparation of 50 mg / ml hypoxanthine: Weigh 1 g hypoxanthine and dissolve it in 20 ml CMC-Na solution.
[0148] (3) Preparation of 0.5 mg / ml benzbromarone: Weigh 20 mg of benzbromarone and dissolve it in 40 ml of CMC-Na solution to a concentration of 0.5 mg / ml.
[0149] (4) 1.0 mg / ml raw material control group preparation: Weigh 40 mg of apigenin and 40 mg of carnosine, dissolve in 40 ml of CMC-Na solution to a concentration of 1.0 mg / ml.
[0150] (5) Preparation of pseudo-positive drug compound 3: Compound 3 (1 g) was accurately weighed and prepared into 0.5 mg / mL, 1.0 mg / mL, and 2.0 mg / mL dose test solutions using the above CMC-Na solution. Each group of test animals was given the drug once a day (weighed before daily administration) for 7 consecutive days. Experimental methods for each animal group: Animals in groups 1, 3, 4, 5, 6, and 7 were given intragastric administration (ig), and CMC-Na was given intragastrically (ig) to group 2 model; the specific conditions are shown in Table 1:
[0151] Table 1 Groups, dosing methods and dosing volumes
[0152]
[0153]
[0154] 30 minutes after the last administration on the 8th day, all groups except the saline group were intraperitoneally (ip) injected with 50 mg / ml hypoxanthine prepared at a dose of 1000 mg / kg body weight. 30-40 minutes after administration, the eyeballs were immediately removed and blood was collected in centrifuge tubes. At room temperature, the serum was allowed to seep out and then centrifuged (15000 rpm, 4 min). The upper serum was drawn and placed in a sample tube with a cap. According to the obtained serum volume, all of it was prepared to the required volume with saline, and the blood uric acid concentration was measured on a Beckman LX20 automatic biochemical analyzer.
[0155] The test showed that compound 3 had different effects on reducing serum uric acid levels in hyperuricemia mice, and within the scope of this experimental design, the effect of the positive control benzbromarone group was not significant (Table 2).
[0156] Table 2 Effects of test samples on blood uric acid in experimental mice (μM)
[0157]
[0158] Example 3
[0159] Example 2: Determination of the body weight of experimental mice
[0160] After testing, the weight of each group in Example 2 (normal saline group, CMC model group, low-dose group of compound 3, medium-dose group of compound 3, high-dose group of compound 3, benzbromarone group) increased after feeding for 7 days, and within the scope of this experimental design, the weight gain level of each group of animals was not much different (Table 3).
[0161] Table 3 Effects of test drugs on the body weight of experimental mice (g)
[0162]
[0163]
[0164] Note: There was no significant difference in weight gain among the groups.
[0165] Example 4
[0166] Acute toxicity test in rats
[0167] Acute toxicity experiments were conducted on compound 3 and blank group with 10 rats (~240g / rat). The experimental group was fed (orally) with compound 3 at a dose 50 times that of the medium-dose group (concentration 50mg / ml, dosing volume 0.1ml / 10g, once a day), while the blank group was fed normally without any sample.
[0168] After 7 days of continuous feeding, no significant difference was found in the body weight of rats in the experimental group and the blank group, which indicates that compound 3 is relatively safe.
[0169] The above content is a schematic description of the present invention and its implementation methods, which is not restrictive. What is shown in the embodiment is only one of the implementation methods of the present invention, and the actual implementation method is not limited thereto. Therefore, if a person of ordinary skill in the art is inspired by it and designs implementation methods and embodiments similar to the technical solution without creative design without departing from the purpose of the invention, they should all fall within the scope of protection of the present invention.
Claims
1. An apigenin derivative or a solvate or a pharmaceutically acceptable salt thereof, characterized in that: The apigenin derivative has the structure shown in the following formula (I):
2. The method for preparing the apigenin derivative or its solvate or pharmaceutically acceptable salt according to claim 1, characterized in that: The method comprises the steps of reacting apigenin with carnosine.
3. The method for preparing the apigenin derivative or its solvate or pharmaceutically acceptable salt according to claim 2, characterized in that: The preparation method comprises: i. a step of reacting apigenin with dimethyl sulfoxide; ii. a step of reacting the product of step i with carnosine.
4. The method for preparing the apigenin derivative according to claim 3, characterized in that: The preparation method also comprises: iii. A step of adding triethylamine to the product of step ii.
5. Use of the apigenin derivative or its solvate or pharmaceutically acceptable salt according to claim 1 in the preparation of a drug for lowering blood uric acid.
6. The use according to claim 5, characterized in that: The blood uric acid lowering drugs include: Drugs that lower blood uric acid by promoting uric acid excretion; or Drugs that lower blood uric acid by inhibiting uric acid production; or Medications that lower serum uric acid by inhibiting uric acid reabsorption; or A drug that lowers blood uric acid and is characterized by catalyzing the conversion of uric acid.
7. The use according to claim 5, characterized in that: The blood uric acid lowering drug is used for preventing, treating or alleviating hyperuricemia.
8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the apigenin derivative according to claim 1 or a solvate or a pharmaceutically acceptable salt thereof as the sole active ingredient or as one of the active ingredients.
9. The pharmaceutical composition according to claim 8, further comprising a pharmaceutically acceptable excipient or carrier.
10. A functional food, characterized in that: The functional food comprises the apigenin derivative according to claim 1 or a solvate or a pharmaceutically acceptable salt thereof.
Citation Information
Patent Citations
Apigenin derivatives and application of apigenin derivatives in treatment of hyperuricemia
CN107674056A
Icarisid I type compound, derivatives, pharmaceutical composition and application thereof
CN109369748A
Flavonoid compound and preparation method and application thereof
CN110903272A
New carnosine derivative and composition
JP2008019188A
Apigenin analogs, compositions, and methods related thereto
US20170204078A1
